資料搜尋諮詢服務
找不到您所需要的資料嗎?
我們能協助您找到最符合您研究需求的資訊
請撥打 +886-2-2799-3110
或透過電子郵件與我們聯絡 mi@hintoninfo.com
IHS_EWBIEEE xploreSTRATEGY ANALYTICSIHS_EWB_GF

Global Biosimilar Market 2010-2014

  • LinkedIn
  • facebook
  • Twitter
出 版 商:Infiniti Research
出版日期:2012/02/10
頁  數:29頁
文件格式:PDF
價  格:
USD 1,500 (Single-User License)
USD 1,800 (Multi-User License)
USD 2,500 (Global-User License)
線上訂購或諮詢
TechNavio’s analysts forecast the Global Biosimilar market to grow at a CAGR of 52.2 percent over the period 2010–2014. One of the key factors contributing to this market growth is the rise in patent expirations of branded biopharmaceuticals. The Global Biosimilar market has also been witnessing the trend of outsourcing of biosimilar manufacturing to Asian countries. However, the risk of drug development failure could pose a challenge to the growth of this market.

TechNavio’s report, the Global Biosimilar Market 2010–2014, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Biosimilar market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market space include Sandoz International GmbH, Teva Pharmaceutical, Industries Ltd., Hospira Inc., and Mylan Inc.

Key questions answered in this report
What will the market size be in 2014 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
01. Executive Summary
02. Introduction
03. Market Coverage
04. Market Landscape
05. Vendor Landscape
06. Buying Criteria
07. Market Growth Drivers
08. Drivers and their Impact
09. Market Challenges
10. Market Trends
11. Key Vendor Analysis
11.1 Sandoz International GmbH
11.2 Teva Pharmaceutical Industries Ltd.
11.3 Hospira Inc.
11.4 Mylan Inc.
12. Other Reports in this Series

List of Exhibits:
Exhibit 1: Global Biosimilar Market 2010–2014 (US$ million)
Exhibit 2: Global Biosimilar Market by Geographical Segmentation 2010
Exhibit 3: Global Biosimilar Market by Vendor Segmentation 2010
回上頁